| 2021/02/26 17:35:09 | |
|---|---|
| Price | |
| 223.975 USD | |
| Difference | -2.08% (-4.75) |
General attributes
| ISIN | US0311621009 |
| Symbol | AMGN |
| Exchange | London Stock Exchange |
| Currency | USD |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 108,216 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | 222.60 USD (320) |
| Ask (Ask size) | 225.35 USD (320) |
| Open | 225.35 USD |
| High | 225.35 USD |
| Low | 225.35 USD |
| Close (prev. day) | 228.725 USD |
| VWAP | 225.35 USD |
| Volume (pcs) | 90 |
| Trading volume | 676.05 |
| Number of trades | 4 |
| Last size | - |
Futures and Options
| Related Futures | 15 |
| Related Options | - |
PDF Downloads
| Company report: AMGEN INC. |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2021/02/15 |
|
Global Equity Ratings |
|
| 2021/02/04 |
|
Global Equity Ratings |
|
| 2021/01/08 |
|
Global Equity Ratings |
|
| 2020/12/21 |
|
Global Equity Ratings |
|
| 2020/12/02 |
|
Global Equity Ratings |
|
| 2021/02/26 17:35:09 | |
|---|---|
| Price | |
| 223.975 USD | |
| Difference | -2.08% (-4.75) |
General attributes
| ISIN | US0311621009 |
| Symbol | AMGN |
| Exchange | London Stock Exchange |
| Currency | USD |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 108,216 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | 222.60 USD (320) |
| Ask (Ask size) | 225.35 USD (320) |
| Open | 225.35 USD |
| High | 225.35 USD |
| Low | 225.35 USD |
| Close (prev. day) | 228.725 USD |
| VWAP | 225.35 USD |
| Volume (pcs) | 90 |
| Trading volume | 676.05 |
| Number of trades | 4 |
| Last size | - |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | -9.46% | +3.74% | +19.98% |
| Perf (abs.) | -23.40 | +8.08 | +37.31 |
| Beta | 0.83 | 0.77 | 0.80 |
| Volatility | 27.10 | 32.38 | 25.65 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 229.240 USD (59) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 240.162 USD (85) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 233.214 USD (199) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 233.224 USD (168) |
| YTD High | date | 256.744 USD (2021/01/28) |
| YTD Low | date | 224.900 USD (2021/01/05) |
| 52 Weeks High | date | 264.800 USD (2020/07/06) |
| 52 Weeks Low | date | 186.797 USD (2020/03/12) |
All listings for AMGEN INC.
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Xetra | 2021/02/26 | 17:35 | 185.44 EUR | 0.25 | 82 |
| Vienna Stock Exchange | 2021/02/26 | 17:32 | 185.42 EUR | 0.04 | 11 |
| Tradegate | 2021/02/26 | 22:26 | 186.30 EUR | 0.41 | 58 |
| Stuttgart | 2021/02/26 | 19:28 | 186.28 EUR | 0.02 | 6 |
| SIX Swiss Exchange | 2019/06/27 | 17:35 | 184.90 CHF | 0.00 | 2 |
| Nasdaq | 2021/02/26 | 22:00 | 224.92 USD | 756.47 | 51,385 |
| Munich | 2021/02/26 | 09:24 | 187.36 EUR | 0.04 | 2 |
| London Stock Exchange | 2021/02/26 | 17:35 | 223.975 USD | 0.00 | 4 |
| Hong Kong Stock Exchange | 2021/02/11 | 02:20 | 1,761.00 HKD | - | - |
| Hanover | 2021/02/26 | 08:04 | 186.54 EUR | 0.00 | 2 |
| Hamburg | 2021/02/26 | 16:29 | 184.94 EUR | 0.00 | 2 |
| Frankfurt | 2021/02/26 | 16:30 | 185.00 EUR | 0.04 | 4 |
| Duesseldorf | 2021/02/26 | 19:31 | 186.10 EUR | 0.00 | 16 |
| Borsa Italiana MTF Trading After Hours | 2021/01/12 | 18:12 | 194.86 EUR | 0.00 | 1 |
| Borsa Italiana MTF Global Equity Market | 2021/02/26 | 17:35 | 184.92 EUR | 0.02 | 5 |
| Berlin | 2021/02/26 | 08:08 | 186.12 EUR | 0.00 | 2 |
Company Logo
Contact Details
| AMGEN INC. |
| - - |
| One Amgen Center Drive - 91320-1799 Thousand Oaks, CA |
| Telefon: +1-805-447-1000 |
| Fax: +1-805-447-1010 |
| E-mail: investor.relations@amgen.com |
PDF Downloads
| Company report: AMGEN INC. | |
Company Profile
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. |
Members of Management Board
| Robert A. Bradway | Chairman of Board of Directors |
| Wanda M. Austin | Member of Board of Directors |
| Tyler Jacks | Member of Board of Directors |
| Ronald D. Sugar | Member of Board of Directors |
| Robert A. Eckert | Member of Board of Directors |
| R. Sanders Williams | Member of Board of Directors |
| Greg C. Garland | Member of Board of Directors |
| Fred Hassan | Member of Board of Directors |
| Ellen J. Kullman | Member of Board of Directors |
| Charles M. Holley Jr. | Member of Board of Directors |
| Brian J. Druker | Member of Board of Directors |
| Amy E. Miles | Member of Board of Directors |
| Robert Bradway | Chairman of Managing Board |
| Victoria H. Blatter | Member of Executive Committee |
| Tia Bush | Member of Executive Committee |
| Susan Sweeney | Member of Executive Committee |
| Steven K. Galson | Member of Executive Committee |
| Rob Lenz | Member of Executive Committee |
| Raymond Deshaies | Member of Executive Committee |
| Peter H. Griffith | Member of Executive Committee |
| Nancy Grygiel | Member of Executive Committee |
| Murdo Gordon | Member of Executive Committee |
| Mike Zahigian | Member of Executive Committee |
| Mike Nohaile | Member of Executive Committee |
| Lori Johnston | Member of Executive Committee |